WE GRATEFULLY THANK ALL OF OUR
2018 BIENNIAL MEETING SPONSORS
Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information about Astellas Pharma US, Inc., please visit our website at www.astellas.com.
Gilead Sciences, a research-based biopharmaceutical company, discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, haematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions. Gilead has a rapidly expanding product portfolio, a growing pipeline of investigational drugs, and over 8,000 employees in offices across six continents. Millions of people around the world are living healthier lives because of therapies developed by Gilead. www.gilead.com
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients' lives. Cidara intends to begin global Phase 3 trials in 2018 in the treatment and prophylaxis of invasive fungal infections to advance its novel echinocandin antifungal, rezafungin acetate (formerly CD101 IV). Cidara is also developing bispecific antibiotic immunotherapies through our Cloudbreak platform for the treatment of multi-drug resistant Gram-negative bacterial infections. For more information, please visit www.cidara.com.
Matinas BioPharma is a biopharmaceutical company focused on enabling the delivery of life-changing medicines using its lipid nano-crystal ("LNC") drug delivery platform. Matinas' proprietary disruptive technology utilizes LNCs which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Matinas' product candidate, MAT2203, utilizes its LNC formulation technology for safe and effective delivery of broad-spectrum fungicidal agent, amphotericin B. Based on positive patient clinical data, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in acute lymphoblastic leukemia patients. www.matinasbiopharma.com
SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
IMMY focuses primarily on manufacturing rapid, high-quality fungal diagnostics. With products for Cryptococcus (CrAg LFA), Histoplasma, Coccidioides (Coccidioides Ab LFA), Aspergillus (Aspergillus GM LFA), and Blastomyces, along with Mycobacteria specimen preparation reagents (MycoDDR), IMMY is setting the standard with accurate and affordable diagnostics for infectious diseases. Our goal is to create and distribute diagnostics that give health professionals and laboratorians a clear path of treatment for patients worldwide. IMMY is bridging the gap between fungal infections and proper treatment by Saving Lives One Diagnostic at a Time. www.immy.com
MycoMed Technologies is a diagnostics firm developing urine-based tests for infectious diseases. We were spun out of Johns Hopkins based on the research of our CEO, Dr. Kieren Marr. Our first product is called MycoFlow-ASP, which is a urine-based, dipstick test for detecting pulmonary aspergillus infection. We are proceeding through clinical development and expect to have MycoFlow-ASP FDA-cleared early in 2019. We have additional development projects in place targeting a variety of fungal diseases as well as tuberculosis. Visit www.mycomedtechnologies.com for more information.
Stop waiting days for blood culture results! T2 Biosystems offers the first and ONLY species-specific sepsis pathogen diagnostic panel -- requiring no blood culture -- delivering faster, easier and more accurate results in an average of 4.3 hours. Run on the fully-automated T2Dx® Instrument utilizing T2 Magnetic Resonance (T2MR®) technology, the T2Candida® Panel identifies the five clinically relevant species of Candida directly from whole blood which enables physician to initiate appropriate therapy on day zero. The T2Dx Instrument and the T2Candida Panel are FDA cleared and in use in over 30 hospitals worldwide. T2 Biosystems, Now You Know NOW. For more information, visit www.t2biosystems.com
Viamet Pharmaceuticals discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior efficacy and safety profiles compared to currently marketed drugs.
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on it vaccine technologies and other therapeutic approaches. Vical's antifungal product candidate, VL-2397, has a novel mechanism of action for the treatment of invasive fungal infections and low propensity for drug-drug interactions. A Phase 2 trial in invasive aspergillosis (IA) was initiated in February 2018. The US FDA has advised that VL-2397 is eligible for limited use indication approval in IA. In addition, FDA has granted Vical QIDP, Orphan Drug and Fast Track designations for VL-2397 in the treatment of IA.
MiraVista Diagnostics is a CAP and CLIA accredited mycology reference laboratory with an exclusive focus on developing and processing diagnostic tests for serious fungal infections. We offer the highest standards in accuracy and sensitivity for detection and monitoring of Blastomyces dermatitidis, Histoplasma capsulatum, Cryptococcus, Coccidioides, Aspergillus and (1–3)-β-D glucan. MiraVista Diagnostics was founded in 2002 and serves the medical community in the U.S. and Canada. We offer same-day testing, superior sensitivity and specificity and direct access to the laboratory’s team of experienced infectious disease specialists. MiraVista serves reference laboratories, hospitals, healthcare systems and university medical centers. For more information, please visit www.miravistalabs.com or call 317-455-2153.